Table 2.

Patient characteristics for RPFNA

Women enrolled in study61
Bilateral RPFNA30
Unilateral RPFNA31
RPFNA samples collected91
No. RPFNAs with insufficient epithelial cell count21
No. RPFNAs submitted for analysis70
Average age and range (y)46 (25-64)
Race, n (%)
    Caucasian50 (82)
    African American8 (13)
    Ashkenazi Jewish3 (5)
Menopausal status, n (%)
    Postmenopausal23 (38)
    Premenopausal/perimenopausal38 (62)
Hormone replacement use, n (%)
    Current1 (2)
    Ever use12 (20)
    Never use48 (78)
Antiestrogen therapy (at the time of RPFNA), n (%)
    Tamoxifen2 (3)
    Raloxifene2 (3)
    Aromatase inhibitor3 (5)
Family history of breast cancer, n (%)28 (46)
Prior abnormal biopsies, n (%)34 (56)
    LCIS3 (5)
    DCIS8 (13)
    ADH11 (18)
    History of contralateral breast cancer12 (20)
Known BRCA1 mutation carriers, n (%)2 (3)
Known BRCA2 mutation carriers, n (%)4 (7)
  • Abbreviations: LCIS, lobular carcinoma in situ; ADH, atypical ductal hyperplasia.